Tibet Duo Rui Pharmaceutical Past Earnings Performance
Past criteria checks 3/6
Tibet Duo Rui Pharmaceutical's earnings have been declining at an average annual rate of -46.4%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 17.6% per year. Tibet Duo Rui Pharmaceutical's return on equity is 2%, and it has net margins of 5.6%.
Key information
-46.4%
Earnings growth rate
-75.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -17.6% |
| Return on equity | 2.0% |
| Net Margin | 5.6% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Tibet Duo Rui Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 335 | 19 | 186 | 20 |
| 31 Dec 23 | 334 | 19 | 201 | 24 |
| 30 Sep 23 | 345 | 17 | 216 | 28 |
| 30 Jun 23 | 386 | 21 | 239 | 30 |
| 31 Mar 23 | 406 | 9 | 265 | 29 |
| 01 Jan 23 | 401 | 21 | 275 | 26 |
| 30 Sep 22 | 436 | 42 | 307 | 20 |
| 30 Jun 22 | 471 | 45 | 346 | 24 |
| 31 Mar 22 | 481 | 56 | 351 | 24 |
| 01 Jan 22 | 530 | 69 | 376 | 24 |
| 30 Sep 21 | 555 | 81 | 394 | 24 |
| 31 Dec 20 | 490 | 92 | 350 | 23 |
| 31 Dec 19 | 449 | 72 | 335 | 27 |
| 31 Dec 18 | 349 | 43 | 255 | 16 |
Quality Earnings: 301075 has a large one-off gain of CN¥12.8M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 301075's current net profit margins (5.6%) are higher than last year (2.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301075's earnings have declined by 46.4% per year over the past 5 years.
Accelerating Growth: 301075's earnings growth over the past year (104.2%) exceeds its 5-year average (-46.4% per year).
Earnings vs Industry: 301075 earnings growth over the past year (104.2%) exceeded the Pharmaceuticals industry -1.1%.
Return on Equity
High ROE: 301075's Return on Equity (2%) is considered low.